1 2 3 4 5 6
читать далее ... тами МК1-рецепторов и другими препаратами позволила существенно снизить эметогенность проводимой химиотерапии, сделать проведение химиотерапевтического лечения во многих случаях амбулаторным и экономичным. Литература 1. Sctinell P.M.. Chemotherapy - induced nausea and vomiting: the importance of acute antiemetic control. The Oncologist 2003, Vol. 8, No 2, 187-198. 2. Belle S. V., Lichinitser M.R. et all. Prevention of Cisplatin - Induced acute and delayed emesis by the selective Neurokinin - 1 antagonists, L-758, 298 and MK - 869. Cancer 2002; 94:3032-41. 3. Kris M.G., Hesketh P.J., et all. Consensus proposals for the prevention of acute and delayed vomiting and nausea following high - emetic - risk chemotherapy. Support Care Cancer 2005, 13:85-96. 4. By Rolf Kaiser, Orhan Sezer, An/a Papies, Steffen Bauer, Claudia Schelenz, Pierre-Benoit Tremblay, Kurf Possinger, Ivar Roots, J?rgen Brockm?ller. Patient-Tailored Antiemetic Treatment With 5-Hydroxytryptamine Type 3 Receptor Antagonists According to Cytochrome P-450 2D6 Genotypes Journal of Clinical Oncology, I/O/ 20, Issue 12 (June), 2002:2805-2811 5. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology v. 1. 2004. 6. Perugia International cancer conference VII. Consensus conference on antiemetic therapy. Multinational Association of Supportive Care In Cancer September 2005. 7. Thomas M. Beck: Arthur A. Ciociola: Stephen E. Jones; Walter H. Harvey; N. Simon Tchekmedyian; Alex Chang; Daniel Galvin; Nan E. Hart, Ondansetron Study Group* Efficacy of Oral Ondansetron in the Prevention of Emesis in Outpatients Receiving Cyclopbosphamide-based Chemotherapy. Annals of Internal medicine, 15 March 1993, Volume 118 Issue 6, Pages 407-413 8. Goodin S., Cunningham R. 5-HT3 - receptor antagonists for the treatment of nausea and vomiting: a reappraisal of their side-effect profile. The Oncologist 2002, Vol. 7, 424 -436. 9. Steven M. Grunberg, and Paul J. Hesketh. Control of Chemotherapy-Induced Emesis The New England journal of medicine, Volume 329:1790-1796, December 9, 1993, Number 24 10. Verna A. Rohodes, Eds and Roxanne W. McDaniel, Ph D. Nausea, vomiting, and retching: complex problems in palliative care. CA Cancer J. Clinical 2001, 51:232-248. 11. Darkow Т., Pharm. D., etall. Impact of ant/emetic selection on postoperative nausea and vomiting and patient satisfaction. Pharmacotherapy 21 (5):540 - 548. 2001. 12 HerrstedtJ., KoellerJ.M., Roila F., WarrD., etall. Acute emesis: moderately emetogenic chemotherapy. Support Care Cancer 2005, 13:97-103. 13. Herrington Jon D., Pharm. D., Peter Kwan, etall. Randomized, multicenter comparison of oral Granisetron and oral Ondansetron for emetogenic chemotherapy. Pharmacotherapy 20 (1-1): 1318- 1323. 2000. 14. The Italian Group for Antiemetic Research Dexametasone alone or in combination with Ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. The New England journal of medicine, Volume 342:1554-1559, may 2Источник: Абрамов М.Е., Личиницер М.Р. Русский медицинский журнал. 2006. Т.14. №6. С.495-500